The company said the rights issue has been subscribed for about 94.6%, with 60.5% subscribed for with and without the exercise of subscription rights, and the other 34.1% subscribed for by guarantors.
Spago said funds raised will go toward beginning the clinical phase I/IIa-study for its lutetium-177-based radiopharmaceutical candidate 177Lu-SN201, planned to start in 2022.
Copyright © 2022 AuntMinnieEurope.com